Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus

Journal of Virology

Volumn 84, Issue 18, 2010, Pages 9415-9426

  Powell, Rebecca L R ^a   Kinge, Thompson ^b   Nyambi, Phillipe N ^a,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MINISTRY OF PUBLIC HEALTH   (Cameroon)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CAMEROON; CD4 LYMPHOCYTE COUNT; CORRELATION ANALYSIS; DILUTION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; IMMUNE RESPONSE; NONHUMAN; PRIMARY INFECTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VACCINATION; VIRUS ISOLATION; VIRUS LOAD; VIRUS STRAIN; VIRUS TITRATION; AFRICA; BLOOD; CLASSIFICATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC50; IMMUNOLOGY; SERODIAGNOSIS; UNITED STATES; VIROLOGY;

AFRICA; ANTIBODIES, NEUTRALIZING; CAMEROON; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; NEUTRALIZATION TESTS; UNITED STATES;

EID: 77956048307     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02732-09     Document Type: Article

References (31)

1. Blish, C. A., O. C. Dogan, N. R. Derby, M. A. Nguyen, B. Chohan, B. A. Richardson, and J. Overbaugh. 2008. HIV-1 superinfection occurs despite relatively robust neutralizing antibody responses. J. Virol. 82:12094-12103.
2. Cecilia, D., V. N. KewalRamani, J. O'Leary, B. Volsky, P. Nyambi, S. Burda, S. Xu, D. R. Littman, and S. Zolla-Pazner. 1998. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J. Virol. 72:6988-6996.
3. Chohan, B., L. Lavreys, S. M. Rainwater, and J. Overbaugh. 2005. Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J. Virol. 79:10701-10708. (Pubitemid 41098609)
4. Doria-Rose, N. A., R. M. Klein, M. G. Daniels, S. O'Dell, M. Nason, A. Lapedes, T. Bhattacharya, S. A. Migueles, R. T. Wyatt, B. T. Korber, J. R. Mascola, and M. Connors. 2010. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84:1631-1636.
5. Fenyo, E. M., A. Heath, S. Dispinseri, H. Holmes, P. Lusso, S. Zolla-Pazner, H. Donners, L. Heyndrickx, J. Alcami, V. Bongertz, C. Jassoy, M. Malnati, D. Montefiori, C. Moog, L. Morris, S. Osmanov, V. Polonis, Q. Sattentau, H. Schuitemaker, R. Sutthent, T. Wrin, and G. Scarlatti. 2009. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 4:e4505.
6. Gerhardt, M., D. Mloka, S. Tovanabutra, E. Sanders-Buell, O. Hoffmann, L. Maboko, D. Mmbando, D. L. Birx, F. E. McCutchan, and M. Hoelscher. 2005. In-depth, longitudinal analysis of viral quasispecies from an individual triply infected with late-stage human immunodeficiency virus type 1, using a multiple PCR primer approach. J. Virol. 79:8249-8261.
7. Gottlieb, G. S., D. C. Nickle, M. A. Jensen, K. G. Wong, J. Grobler, F. Li, S. L. Liu, C. Rademeyer, G. H. Learn, S. S. Karim, C. Williamson, L. Corey, J. B. Margolick, and J. I. Mullins. 2004. Dual HIV-1 infection associated with rapid disease progression. Lancet 363:619-622.
8. Grobler, J., C. M. Gray, C. Rademeyer, C. Seoighe, G. Ramjee, S. A. Karim, L. Morris, and C. Williamson. 2004. Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J. Infect. Dis. 190:1355-1359.
9. Herbinger, K. H., M. Gerhardt, S. Piyasirisilp, D. Mloka, M. A. Arroyo, O. Hoffmann, L. Maboko, D. L. Birx, D. Mmbando, F. E. McCutchan, and M. Hoelscher. 2006. Frequency of HIV type 1 dual infection and HIV diversity: analysis of low- and high-risk populations in Mbeya Region, Tanzania. AIDS Res. Hum. Retroviruses 22:599-606.
10. Heyndrickx, L., W. Janssens, L. Zekeng, R. Musonda, S. Anagonou, G. Van der Auwera, S. Coppens, K. Vereecken, K. De Witte, R. Van Rampelbergh, M. Kahindo, L. Morison, F. E. McCutchan, J. K. Carr, J. Albert, M. Essex, J. Goudsmit, B. Asjo, M. Salminen, A. Buve, Study Group on Heterogeneity of HIV Epidemics in African Cities, and G. van Der Groen. 2000. Simplified strategy for detection of recombinant human immunodeficiency virus type 1 group M isolates by gag/env heteroduplex mobility assay. J. Virol. 74:363-370.
11. Hurwitz, J. L., K. S. Slobod, T. D. Lockey, S. Wang, T. H. Chou, and S. Lu. 2005. Application of the polyvalent approach to HIV-1 vaccine development. Curr. Drug Targets Infect. Disord. 5:143-156.
12. Johnston, M. I., and A. S. Fauci. 2008. An HIV vaccine - challenges and prospects. N. Engl. J. Med. 359:888-890.
13. Korber, B., et al. (ed.). 2004. HIV immunology and sequence databases, Los Alamos, NM. Los Alamos National Laboratory, Los Alamos, NM. www.hiv.lanl.gov.
14. Laal, S., S. Burda, S. Sharpe, and S. Zolla-Pazner. 1993. A rapid, automated microtiter assay for measuring neutralization of HIV-1. AIDS Res. Hum. Retroviruses 9:781-785.
15. Landau, N. R., K. A. Page, and D. R. Littman. 1991. Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J. Virol. 65:162-169.
16. Manigart, O., V. Courgnaud, O. Sanou, D. Valea, N. Nagot, N. Meda, E. Delaporte, M. Peeters, and P. Van de Perre. 2004. HIV-1 superinfections in a cohort of commercial sex workers in Burkina Faso as assessed by an autologous heteroduplex mobility procedure. AIDS 18:1645-1651.
17. McCutchan, F. E., M. Hoelscher, S. Tovanabutra, S. Piyasirisilp, E. Sanders-Buell, G. Ramos, L. Jagodzinski, V. Polonis, L. Maboko, D. Mmbando, O. Hoffmann, G. Riedner, F. von Sonnenburg, M. Robb, and D. L. Birx. 2005. In-depth analysis of a heterosexually acquired human immunodeficiency virus type 1 superinfection: evolution, temporal fluctuation, and intercompartment dynamics from the seronegative window period through 30 months postinfection. J. Virol. 79:11693-11704.
18. Piantadosi, A., B. Chohan, V. Chohan, R. S. McClelland, and J. Overbaugh. 2007. Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog. 3:e177.
19. Piantadosi, A., D. Panteleeff, C. A. Blish, J. M. Baeten, W. Jaoko, R. S. McClelland, and J. Overbaugh. 2009. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 83:10269-10274.
20. Powell, R. L., L. Lezeau, T. Kinge, and P. Nyambi. 2010. Longitudinal quasispecies analysis of viral variants in HIV-1 dually-infected individuals highlights the importance of sequence identity in viral recombination. AIDS Res. Hum. Retroviruses 26:253-264.
21. Powell, R. L., M. M. Urbanski, S. Burda, T. Kinge, and P. N. Nyambi. 2009. High frequency of HIV-1 dual infections among HIV-positive individuals in Cameroon, West Central Africa. J. Acquir. Immune Defic. Syndr. 50:84-92.
22. Powell, R. L., M. M. Urbanski, and P. N. Nyambi. 2008. A heteroduplex assay for the rapid detection of dual human immunodeficiency virus type 1 infections. J. Virol. Methods 149:20-27.
23. Sakhatskyy, P., S. Wang, C. Zhang, T. H. Chou, M. Kishko, and S. Lu. 2008. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Virology 371:98-107.
24. Sather, D. N., J. Armann, L. K. Ching, A. Mavrantoni, G. Sellhorn, Z. Caldwell, X. Yu, B. Wood, S. Self, S. Kalams, and L. Stamatatos. 2009. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
25. Smith, D. M., M. C. Strain, S. D. Frost, S. K. Pillai, J. K. Wong, T. Wrin, Y. Liu, C. J. Petropolous, E. S. Daar, S. J. Little, and D. D. Richman. 2006. Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology 355:1-5.
26. Smith, D. M., J. K. Wong, G. K. Hightower, C. C. Ignacio, K. K. Koelsch, E. S. Daar, D. D. Richman, and S. J. Little. 2004. Incidence of HIV super-infection following primary infection. JAMA 292:1177-1178.
27. Swanson, P., C. de Mendoza, Y. Joshi, A. Golden, R. L. Hodinka, V. Soriano, S. G. Devare, and J. Hackett, Jr. 2005. Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J. Clin. Microbiol. 43:3860-3868.
28. Wang, S., J. S. Kennedy, K. West, D. C. Montefiori, S. Coley, J. Lawrence, S. Shen, S. Green, A. L. Rothman, F. A. Ennis, J. Arthos, R. Pal, P. Markham, and S. Lu. 2008. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26:3947-3957.
29. Wang, S., R. Pal, J. R. Mascola, T. H. Chou, I. Mboudjeka, S. Shen, Q. Liu, S. Whitney, T. Keen, B. C. Nair, V. S. Kalyanaraman, P. Markham, and S. Lu. 2006. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 350:34-47.
30. Zolla-Pazner, S., S. S. Cohen, C. Krachmarov, S. Wang, A. Pinter, and S. Lu. 2008. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology 372:233-246. (Pubitemid 351273743)
31. Zolla-Pazner, S., and S. Sharpe. 1995. A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates. AIDS Res. Hum. Retroviruses 11:1449-1458.